Lucid Diagnostics (NASDAQ: LUCD) net income
Lucid Diagnostics reported a net loss of $58.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $45.5m. Earnings per share were −$0.69.
Lucid Diagnostics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$58.0m | — | −1,232.7% | −$0.69 |
| 2024 | −$45.5m | — | −1,047.6% | −$1.05 |
| 2023 | −$52.7m | — | −2,169.1% | −$1.26 |
| 2022 | −$56.2m | — | −14,899.5% | −$1.55 |
| 2021 | −$28.1m | — | −5,615.6% | −$1.51 |
| 2020 | −$8.3m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Lucid Diagnostics net income compared with its sector
By net income for its latest fiscal year, Lucid Diagnostics ranks 271st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Lucid Diagnostics, −1,232.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 269th | Relmada Therapeutics | −$57.4m | — |
| 270th | Protara Therapeutics | −$57.4m | — |
| 271st | Lucid Diagnostics | −$58.0m | −1,232.7% |
| 272nd | Nautilus Biotechnology | −$59.0m | — |
| 273rd | Adaptive Biotechnologies | −$59.5m | −21.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Lucid Diagnostics
- How much did Lucid Diagnostics earn in fiscal 2025?
- Lucid Diagnostics reported a net loss of $58.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $45.5m.
- What are the earnings per share of Lucid Diagnostics?
- They were −$0.69 in fiscal 2025, compared with −$1.05 in fiscal 2024.
- Where does Lucid Diagnostics rank in its sector by net income?
- It ranks 271st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Lucid Diagnostics come from?
- From the annual report (Form 10-K) that Lucid Diagnostics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Lucid Diagnostics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Lucid Diagnostics: the Lucid Diagnostics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.